CLEVIPREX® (clevidipine) pharmacology and mechanism of action

Cleviprex vials

CLEVIPREX rapidly lowers arterial blood pressure1

Down Arrows

Titratable, fast onset of action1

CLEVIPREX begins to reduce SBP within 2 minutes of initiation dose. An approximately 1 to 2 mg/h increase will generally produce an additional 2 to 4 mm Hg decrease in SBP.

~1-minute half-life1

CLEVIPREX has a half-life of ~1 minute. In most patients, full recovery of BP is achieved 5 to 15 minutes after the infusion is stopped.

Metabolism Icon


Dosing of CLEVIPREX is independent of hepatic and renal function due to metabolism by plasma and tissue esterases.

The pharmacology of CLEVIPREX1

CLEVIPREX is titrated to the desired reduction in BP. The effect of CLEVIPREX appears to plateau at approximately 25% of baseline SBP. The infusion rate for which half the maximal effect is observed is approximately 10 mg/h.


Mechanism of action1

CLEVIPREX works by selectively dilating arterial smooth muscle via calcium channel blockade, reducing systemic vascular resistance without affecting preload.


Stroke Guidelines

CLEVIPREX has been recommended in the AHA/ASA Acute Ischemic Stroke Guidelines since 2018.3

View the Recommendations

Proven efficacy in clinical studies1,2,4-6

CLEVIPREX provided BP reduction in a range of patients and in various clinical settings.

Explore the Clinical Studies

Individualized, titratable administration1

CLEVIPREX offers low-volume, non–weight-based dosing that is independent of renal or hepatic function.

Review Dosing and Administration